Cargando…
PCOS and Hyperprolactinemia: what do we know in 2019?
Polycystic ovary syndrome (PCOS) and hyperprolactinemia (HPRL) are the two most common etiologies of anovulation in women. Since the 1950s, some authors think that there is a pathophysiological link between PCOS and HPRL. Since then, many authors have speculated about the link between these two endo...
Autores principales: | Delcour, Clémence, Robin, Geoffroy, Young, Jacques, Dewailly, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734626/ https://www.ncbi.nlm.nih.gov/pubmed/31523136 http://dx.doi.org/10.1177/1179558119871921 |
Ejemplares similares
-
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
por: Romualdi, Daniela, et al.
Publicado: (2020) -
The Source of Polycystic Ovarian Syndrome
por: Raperport, Claudia, et al.
Publicado: (2019) -
Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies
por: Barber, Thomas M, et al.
Publicado: (2019) -
The insulin signaling pathway is dysregulated in cumulus cells from
obese, infertile women with polycystic ovarian syndrome with an absence of
clinical insulin resistance
por: Chehin, Mauricio B., et al.
Publicado: (2020) -
Controversies in the diagnosis of polycystic ovary
syndrome
por: Rao, Preetham, et al.
Publicado: (2020)